重组人干扰素α2a栓辅助治疗慢性宫颈炎合并人乳头瘤病毒感染患者的效果  

Effect of Recombinant Human Interferonα2a Supposit in the Adjuvant Treatment of Chronic Cervicitis with Human Papillomavirus Infection

作　　者：王妮[1] 王佩 宋雪妮[1] 文雪梅[1] WANG Ni;WANG Pei;SONG Xue-Ni;WEN Xue-Mei(Affiliated Hospital of Xizang Minzu University,Xianyang 712000,China)

机构地区：[1]西藏民族大学附属医院,陕西咸阳712000

出　　处：《中国药物经济学》2023年第11期39-42,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨重组人干扰素α2a栓辅助治疗慢性宫颈炎合并人乳头瘤病毒(HPV)感染患者的效果。方法选取2018年7月至2020年12月西藏民族大学附属医院收治的121例慢性宫颈炎合并HPV感染患者作为研究对象,按照随机数字表法分为常规组(60例)与联合组(61例)。常规组予以电灼光治疗,联合组辅以重组人干扰素α2a栓治疗,比较两组宫颈一般状况、炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及白细胞介素-4(IL-4)]水平以及不良反应发生情况。结果治疗3个月后联合组宫颈症状积分(3.34±0.36)分、HPV病毒载量(6.74±1.45)×10^(3)/ml均低于常规组(3.51±0.43)分、(7.42±1.57)×10^(3)/ml,联合组分泌物恢复时间(13.56±2.34)d、创面愈合时间(6.94±1.28)d均短于常规组(14.74±2.63)d、(7.53±1.34)d,差异有统计学意义(P<0.05);治疗3个月后联合组hs-CRP(1.18±0.37)mg/L、IL-6(1.98±0.25)pg/L、TNF-α(34.72±3.18)μg/L、IL-4(2.47±0.29)μg/L均低于常规组(1.37±0.45)mg/L、(2.12±0.31)pg/L、(36.23±3.84)μg/L、(2.61±0.34)μg/L(P<0.05);联合组不良反应发生率(8.20%)与常规组(5.00%)比较差异无统计学意义(P>0.05)。结论重组人干扰素α2a栓辅助治疗可降低炎症因子水平,减少HPV病毒载量,从而促进宫颈恢复,且不增加不良反应。Objective To explore the effect of recombinant human interferonα2a supposit in the treatment of chronic cervicitis complicated with human papillomavirus(HPV)infection.Methods A total of 121 patients with chronic cervicitis complicated with HPV infection admitted to the Affiliated Hospital of Xizang Minzu University from July 2018 to December 2020 were selected as the study objects,and were divided into routine group(60 cases)and combined group(61 cases)according to random number table method.The conventional group was treated with electrocauterization and the combined group was treated with recombinant human interferonα2a supposit.The general cervical condition,levels of inflammatory factors[hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and interleukin-4(IL-4)]and the occurrence of adverse reactions were compared between the two groups.Results After 3 months of treatment,the cervical symptom score and HPV viral load of the combined group were(3.34±0.36)and(6.74±1.45)×10^(3)/ml is less than that of the conventional group(3.51±0.43)points,(7.42±1.57)×10^(3)/ml,the secretion recovery time(13.56±2.34)d and wound healing time(6.94±1.28)d were shorter than those in the conventional group(14.74±2.63)d and(7.53±1.34)d respectively(P<0.05);After 3 months of treatment,Hs-CRP(1.18±0.37)mg/L,IL-6(1.98±0.25)pg/L,TNF-α(34.72±3.18)μg/L and IL-4(2.47±0.29)μg/L in the combined group were lower than those in the conventional group(1.37±0.45)mg/L,(2.12±0.31)pg/L,(36.23±3.84)μg/L,(2.61±0.34)μg/L,respectively(P<0.05);There was no significant difference in the incidence of adverse reactions between the combined group(8.20%)and the conventional group(5.00%)(P>0.05).Conclusion Interferon adjuvant therapy can reduce the level of inflammatory factors and HPV viral load,so as to promote cervical recovery without increasing adverse reactions.

关 键 词：慢性宫颈炎 重组人干扰素α2a栓 不良反应 人乳头瘤病毒 

分 类 号：R711.32[医药卫生—妇产科学] R984[医药卫生—临床医学]